Side-by-side · Research reference

Melanotan-IIvsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1Reviewed9/43 cited

BFDA-ApprovedVerified14/45 cited

Melanotan-II

MC1R + MC4R agonist · Tanning + sexual response

0.25–1.0 mgPer doseDorr 1996

Phase 1Evidence levelDorr 1996

~1 hrHalf-life

SQ · Abdomen · Loading 5–7 days, then maintenance

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Melanotan-II

Tirzepatide

Primary target

MC1R (skin) + MC3R + MC4R (CNS sexual / appetite)Dorr 1996

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

MC1R agonism → melanocyte tyrosinase → eumelanin synthesis. MC4R → autonomic sexual arousal centresDorr 1996 Simerly 2023

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Skin darkening, photo-protection, increased sexual desire / spontaneous erectionDorr 1996

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

—

Glucose-dependent insulin release preserves physiological feedback

Origin

Cyclic 7-AA modified α-MSH analog; designed at University of ArizonaDorr 1996

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

—

02Dosage Protocols

Parameter

Melanotan-II

Tirzepatide

Loading phase

0.25–0.5 mg/day SQ × 5–7 daysDorr 1996

Builds up to visible tan.

—

Maintenance

0.5–1.0 mg 1–2×/week

After visible tan develops; supports with UV exposure.

—

Frequency

Daily during loading; 1–2× per week maintenance

—

Lower / starter dose

0.1 mg / day

Conservative starter — assess tolerability for nausea.

—

Evidence basis

Phase 1 + anecdotalDorr 1996

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Duration

8–12 weeks per cycle

Indefinite for chronic indication

Reconstitution

Bacteriostatic water; protect from light

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

Evening preferred (24h tan-development cycle)

Once weekly, any time of day

Half-life

~1 hour plasma; effects on melanocytes persist days

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

04Side Effects & Safety

Parameter

Melanotan-II

Tirzepatide

Nausea

Common, especially loading phase

—

Flushing

Common transient

—

Spontaneous erection

Common in men — MC4R cross-effectDorr 1996

—

Increased mole / freckle pigmentation

Existing moles darken; new lesions possible

—

Melanoma risk

Theoretical concern — increased melanocyte activity; CAUTION in melanoma history

—

Appetite suppression

MC4R-mediated; mild

—

Pregnancy / OB

Contraindicated

GI symptoms

—

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

Melanotan-II

·History of melanoma or atypical mole syndrome
·Pregnancy / breastfeeding
·Active uncontrolled hypertension

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

Melanotan-II

·Significant freckling / dysplastic nevus
·Personal or family melanoma history

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

Melanotan-II

Tirzepatide

1. Reconstitution

Add 2 mL bacteriostatic water to 10 mg vial → 5 mg/mL = 500 mcg per 0.1 mL. Light-protected.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Injection site

SQ — abdomen. Rotate sites.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Evening preferred. UV exposure (sunlight or tanning bed) helps develop tan.

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Storage

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Needle

29–31G insulin syringe.

Pen-supplied. Research vial: 27–31G insulin syringe.